Pricing & Access· August 13, 2026 · 22 min read
Topic
IL-23 Inhibitor
Risankizumab, guselkumab, tildrakizumab, IL-23 p19 inhibitors, access, coverage, and formulary positioning.
Approvals· July 3, 2026 · 17 min read
Icotyde (icotrokinra) FDA approval and oral IL-23 psoriasis access
By Ran Chen#FDA Approval#Dermatology#Immunology
Evidence· June 19, 2026 · 13 min read
IL-17 and IL-23 biologics in FAERS: 400,283 adverse-event reports by the numbers
Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access
Pricing & Access· May 16, 2026 · 8 min read